PMID- 8997456
OWN - NLM
STAT- MEDLINE
DCOM- 19970326
LR  - 20071115
IS  - 0091-7370 (Print)
IS  - 0091-7370 (Linking)
VI  - 27
IP  - 1
DP  - 1997 Jan-Feb
TI  - The association of antibodies to beta 2 glycoprotein I with the antiphospholipid 
      syndrome: a meta-analysis.
PG  - 41-6
AB  - The precise target of marker autoantibodies in the antiphospholipid syndrome 
      (APS) has been controversial. Recently, the theory that surface-bound beta 2 
      glycoprotein I (beta 2 GPI) presents a normally encrypted autoepitope and that 
      antibodies to beta 2 GPI (anti-beta 2 GPI) are associated with APS, has been 
      prominent. The literature has been searched from 1990 to 1995 (inclusive) to find 
      studies in which: (1) anti-beta 2 GPI antibodies were measured and, (2) adequate 
      clinical data describing the patients were included. These conditions were met in 
      four studies, from August 1992 to December 1995, in which patient samples ranged 
      from 15 to 39 cases, the total of the four studies being 90 cases. Applying the 
      diagnostic criteria of > or = 2 clinical manifestations of APS, 65 cases had APS 
      while 25 did not. For the group with APS, 58/65 (89 percent) were anti-beta 2 GPI 
      (+); among those who did not meet the criteria, 11/25 (44 percent) were anti-beta 
      2 GPI (+) (p < 0.0001). The presence of either the primary (1 degree) or 
      secondary (2 degrees) form of APS made no difference in association with 
      anti-beta 2 GPI; 13/16 (81 percent) patients with 1 degree APS and 45/49 (92 
      percent) with 2 degrees APS had anti-beta 2 GPI. The presence of lupus 
      anticoagulant (LAC) did not predict APS: 25/58 (38 percent) APS (+) cases were 
      LAC (+); 11 APS (-) were all LC (+) (p < 0.0001). IgG anticardiolipin also showed 
      a closer association with APS absence (25/25 cases; 100 percent) than with APS 
      presence (40/65; 62 percent, p < 0.0001). These data support the contention that 
      anti-beta 2 GPI antibodies are closely associated with APS and that their 
      measurement may facilitate the diagnosis.
FAU - Najmey, S S
AU  - Najmey SS
AD  - Department of Medicine, Seton Hall University, School of Graduate Medical 
      Education, St. Joseph's Hospital and Medical Center, Paterson, NJ 07503, USA.
FAU - Keil, L B
AU  - Keil LB
FAU - Adib, D Y
AU  - Adib DY
FAU - DeBari, V A
AU  - DeBari VA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Clin Lab Sci
JT  - Annals of clinical and laboratory science
JID - 0410247
RN  - 0 (Antibodies)
RN  - 0 (Cardiolipins)
RN  - 0 (Epitopes)
RN  - 0 (Glycoproteins)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Lupus Coagulation Inhibitor)
RN  - 0 (beta 2-Glycoprotein I)
SB  - IM
MH  - Antibodies/*immunology/metabolism
MH  - Antiphospholipid Syndrome/diagnosis/*epidemiology/immunology
MH  - Autoimmune Diseases/immunology
MH  - Cardiolipins/immunology/metabolism
MH  - Epitopes/immunology
MH  - Glycoproteins/*immunology
MH  - Humans
MH  - Immunoglobulin G/blood/immunology
MH  - Information Systems
MH  - Lupus Coagulation Inhibitor/immunology
MH  - Meta-Analysis as Topic
MH  - beta 2-Glycoprotein I
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Ann Clin Lab Sci. 1997 Jan-Feb;27(1):41-6.